HCV care support needed in vulnerable communities

A recent article by MedPage Today provides commentary and perspective on the December publication by our group in the Annals of Internal Medicine. F. Blaine Hollinger MD, at the Eugene B. Casey Hepatitis Research Center at Baylor College of Medicine in Houston offers commentary on the rates of chronic infection and identifies what we view […]

Read more

New publication about STOP HCC program

2.7-3.5 million people in the US have chronic HCV and roughly half don’t know it. This is particularly dangerous because HCV can develop into chronic liver disease and even liver cancer. A new publication from our group in the Annals of Internal Medicine describes the STOP HCC-HCV program to screen, manage, and treat HCV and […]

Read more

Hep C treatment and liver cancer survival

Hepatitis C virus can lead to severe liver damage and hepatocellular carcinoma (HCC), a common corm of liver cancer. Researchers have long known that early detection and treatment of hepatitis C with direct-acting antiviral therapy (DAAs) can reduce the risks of developing HCC. Now there appears to be even more good news. Patients who have […]

Read more

Texas earns a D+

The National Viral Hepatitis Roundtable has released state-by-state report cards on Medicaid access, a major consideration for who can get access to hepatitis c testing treatment. The report takes a close look at treatment access in each state. The key restrictions that earned Texas a D+ grade are related to liver damage, sobriety, and prescriber […]

Read more

Should all adults be screened for Hepatitis C?

The United States Preventive Services Task Force (USPSTF) is considering a new recommendation to screen all adults aged 18-79 for hepatitis C virus (HCV). The USPSTF, a panel of national experts in prevention and medicine, previously recommended one-time, HCV screening for all persons born 1945-1965 (baby boomers) as well as individuals at risk for infection […]

Read more

Hepatitis C screening saves lives

HCV is the most common blood-borne infection in the US and a leading cause of liver failure and liver cancer. But most people who have it do not know they are infected. The good news is that HCV can be cured, often in just three months with daily medication.  Pharmaceutical assistance pathways offer free or […]

Read more

HCV treatment reduces liver cancer mortality risks

We know that identifying and treating HCV early with 8-12 weeks of direct acting anti-viral (DAA) medication can prevent the development of hepatocellular carcinoma (HCC), a very dangerous form of liver cancer. But did you know that treatment can also reduce the risk of death in patients who already have a history of HCC? Researchers […]

Read more

World Hepatitis Day

July 28th, World Hepatitis Day, is a time to join together and raise awareness about the the global burden of viral hepatitis.  Visit WorldHepatitisDay to learn how you can get involved.     View the World Hepatitis Alliance’s video on finding the millions of people who have hepatitis and don’t know it:    

Read more

A new model of HCV treatment access

Although the new drugs to treat HCV are very effective (at least 9 out of 10 people can be cured in 8-12 weeks), they are very expensive, especially for people who do not have insurance. Even for patients with insurance, co-pay costs may make treatment unaffordable. Prices are so high that state-funded programs like Medicaid […]

Read more

Hepatitis C screening saves lives

HCV is the most common blood-borne infection in the US and a leading cause of liver failure and liver cancer. But most people who have it do not know they are infected. The good news is that HCV can be cured, often in just three months with daily medication.  Pharmaceutical assistance pathways offer free or […]

Read more